Figure 4.

Anti-Siglec-9 mAb reduces tumor volume in vivo in a humanized mouse model of ovarian cancer. (A) Dot plots showing selected windows and gating strategy as applied to the identification of major immune cell populations in the hu-mice. Percentage represents the means of values obtained in 2 independent experiments. (B) Representative flow cytometry histograms of FACS analysis immune cell populations in the hu-Mice. Each marker was tested on at least three independent experiments and created from a batch of 27 mice; hCD45+ show n=25 dots, CD20 show n=27 dots, CD56 show n=27 dots. Data were calculated as average % of expressing cell ± SD. All panels are representative of 3 independent experiments. (C) Effects of anti-human Siglec-9 antibody on tumor growth in hu-mice. On day 0, humanized mice (n=5) were injected with 5x105 SKOV3 cells. 100µg of anti-hSiglec-9 antibody or control IgG was administered to each mouse on days 7 and 14. Tumor volume was measured on days 3, 12, 19, 24, and 33. After tumors became detectable, tumor masses were measured with a manual caliper, and tumor volumes were calculated, approximating the tumor mass to a sphere, according to the following equation: tumor volume = ½ (length x width2).